A clinical trial to evaluate the safety and immunogenicity of the LEISH-F1+MPL-SE vaccine for use in the prevention of visceral leishmaniasis

被引:117
作者
Chakravarty, Jaya [2 ]
Kumar, Subodh [2 ]
Trivedi, Sonali [2 ]
Rai, Vijay K. [2 ]
Singh, Anup [2 ]
Ashman, Jill A. [1 ]
Laughlin, Elsa M. [1 ]
Coler, Rhea N. [1 ]
Kahn, Stuart J. [1 ]
Beckmann, Anna Marie [1 ]
Cowgill, Karen D. [1 ]
Reed, Steven G. [1 ]
Sundar, Shyam [2 ]
Piazza, Franco M. [1 ]
机构
[1] IDRI, Seattle, WA 98104 USA
[2] Banaras Hindu Univ, Inst Med Sci, Varanasi 221005, Uttar Pradesh, India
关键词
Leishmaniasis vaccines; Adjuvants; Immunologic; Leishmaniasis; Visceral; CUTANEOUS LEISHMANIASIS; DONOVANI INFECTION; RISK-FACTORS; LIPID-A; INDIA; BIHAR; EPIDEMIOLOGY; COMBINATION; MANAGEMENT; ADJUVANT;
D O I
10.1016/j.vaccine.2011.02.096
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Healthy Indian adult volunteers, with or without a history of leishmaniasis, were evaluated for evidence of previous infection with Leishmania donovani based on the direct agglutination test (DAT). Three cohorts of 6 DAT-negative and 6 DAT-positive subjects were enrolled in an open-label, dose-escalating, uncontrolled clinical trial and received three injections of the LEISH-F1 + MPL-SE vaccine (consisting of 5 mu g, 10 mu g, or 20 mu g recombinant Leishmania polyprotein LEISH-F1 antigen +25 mu g MPL (R)-SE adjuvant). The study injections were given subcutaneously on days 0, 28, and 56, and the subjects were followed through day 168 for safety and immunological endpoints. The vaccine was safe and well-tolerated in DAT-negative and DAT-positive subjects and induced T-cell production of IFN-gamma and other cytokines in response to stimulation with the LEISH-F1 antigen. This clinical trial shows that the LEISH-F1 + MPL-SE vaccine is safe and immunogenic in healthy subjects with and without history of previous infection with Leishmania donovani. (C) 2011 Elsevier Ltd. All rights reserved.
引用
收藏
页码:3531 / 3537
页数:7
相关论文
共 30 条
[1]   Leishmaniasis and poverty [J].
Alvar, Jorge ;
Yactayo, Sergio ;
Bern, Caryn .
TRENDS IN PARASITOLOGY, 2006, 22 (12) :552-557
[2]  
*B DICK CO, 2007, BD CYT BEAD ARR CBA
[3]   Risk factors for kala-azar in Bangladesh [J].
Bern, C ;
Hightower, AW ;
Chowdhury, R ;
Ali, M ;
Amann, J ;
Wagatsuma, Y ;
Haque, R ;
Kurkjian, K ;
Vaz, LE ;
Begum, M ;
Akter, T ;
Cetre-Sossah, CB ;
Ahluwalia, IB ;
Dotson, E ;
Secor, WE ;
Breiman, RF ;
Maguire, JH .
EMERGING INFECTIOUS DISEASES, 2005, 11 (05) :655-662
[4]  
Bora D, 1999, NATL MED J INDIA, V12, P62
[5]   MOLECULAR CHARACTERIZATION OF A KINESIN-RELATED ANTIGEN OF LEISHMANIA-CHAGASI THAT DETECTS SPECIFIC ANTIBODY IN AFRICAN AND AMERICAN VISCERAL LEISHMANIASIS [J].
BURNS, JM ;
SHREFFLER, WG ;
BENSON, DR ;
GHALIB, HW ;
BADARO, R ;
REED, SG .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1993, 90 (02) :775-779
[6]   Putting endotoxin to work for us: Monophosphoryl lipid A as a safe and effective vaccine adjuvant [J].
Casella, C. R. ;
Mitchell, T. C. .
CELLULAR AND MOLECULAR LIFE SCIENCES, 2008, 65 (20) :3231-3240
[7]   Immunization with a polyprotein vaccine consisting of the T-cell antigens thiol-specific antioxidant, Leishmania major stress-inducible protein 1, and Leishmania elongation initiation factor protects against leishmaniasis [J].
Coler, RN ;
Skeiky, YAW ;
Bernards, K ;
Greeson, K ;
Carter, D ;
Cornellison, CD ;
Modabber, F ;
Campos-Neto, A ;
Reed, SG .
INFECTION AND IMMUNITY, 2002, 70 (08) :4215-4225
[8]   Leishmaniasis: current situation and new perspectives [J].
Desjeux, P .
COMPARATIVE IMMUNOLOGY MICROBIOLOGY AND INFECTIOUS DISEASES, 2004, 27 (05) :305-318
[9]   Longitudinal Seroepidemiologic Study of Visceral Leishmaniasis in Hyperendemic Regions of Bihar, India [J].
Gidwani, Kamlesh ;
Kumar, Rajiv ;
Rai, Madhukar ;
Sundar, Shyam .
AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 2009, 80 (03) :345-346
[10]   Visceral leishmaniasis: New health tools are needed [J].
Hailu, A ;
Musa, AM ;
Royce, C ;
Wasunna, M .
PLOS MEDICINE, 2005, 2 (07) :590-594